In the latest session, Sutro Biopharma Inc (NASDAQ: STRO) closed at $3.27 down -4.39% from its previous closing price of $3.42. In other words, the price has decreased by -$0.1500 from its previous closing price. On the day, 530439 shares were traded. STRO stock price reached its highest trading level at $3.4150 during the session, while it also had its lowest trading level at $3.2100.
Ratios:
For a deeper understanding of Sutro Biopharma Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.18 and its Current Ratio is at 5.18. In the meantime, Its Debt-to-Equity ratio is 0.34 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on November 09, 2023, initiated with a Buy rating and assigned the stock a target price of $12.
On October 06, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $10.
Wells Fargo Downgraded its Overweight to Equal Weight on March 21, 2023, whereas the target price for the stock was revised from $15 to $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 29 ’24 when Vasquez Nicki sold 12,185 shares for $5.00 per share. The transaction valued at 60,925 led to the insider holds 12,803 shares of the business.
Shtylla Brunilda sold 15,428 shares of STRO for $72,595 on Aug 28 ’23. The Chief Business Officer now owns 0 shares after completing the transaction at $4.71 per share. On Aug 25 ’23, another insider, Shtylla Brunilda, who serves as the Chief Business Officer of the company, sold 11,613 shares for $4.59 each. As a result, the insider received 53,282 and left with 12,928 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, STRO now has a Market Capitalization of 207.85M and an Enterprise Value of -109.13M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.10 while its Price-to-Book (P/B) ratio in mrq is 1.77. Its current Enterprise Value per Revenue stands at -2.24 whereas that against EBITDA is 0.73.
Stock Price History:
Over the past 52 weeks, STRO has reached a high of $6.11, while it has fallen to a 52-week low of $2.01. The 50-Day Moving Average of the stock is 4.4572, while the 200-Day Moving Average is calculated to be 4.0689.
Shares Statistics:
For the past three months, STRO has traded an average of 853.22K shares per day and 1.06M over the past ten days. A total of 60.95M shares are outstanding, with a floating share count of 58.41M. Insiders hold about 4.17% of the company’s shares, while institutions hold 92.06% stake in the company. Shares short for STRO as of Feb 29, 2024 were 2.41M with a Short Ratio of 2.82, compared to 2.61M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.95% and a Short% of Float of 4.00%.
Earnings Estimates
There are 9 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.82 for the current quarter, with a high estimate of -$0.71 and a low estimate of -$0.94, while EPS last year was -$0.68. The consensus estimate for the next quarter is -$0.86, with high estimates of -$0.78 and low estimates of -$0.94.
Analysts are recommending an EPS of between -$3.03 and -$3.21 for the fiscal current year, implying an average EPS of -$3.14. EPS for the following year is -$3.44, with 9 analysts recommending between -$2.57 and -$3.99.
Revenue Estimates
A total of 9 analysts believe the company’s revenue will be $11.81M this quarter.It ranges from a high estimate of $18M to a low estimate of $5M. As of the current estimate, Sutro Biopharma Inc’s year-ago sales were $8.63M, an estimated increase of 36.80% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $11.97M, a decrease of -5.60% less than the figure of $36.80% in the same quarter last year. There is a high estimate of $17.95M for the next quarter, whereas the lowest estimate is $6M.
A total of 9 analysts have provided revenue estimates for STRO’s current fiscal year. The highest revenue estimate was $58M, while the lowest revenue estimate was $45M, resulting in an average revenue estimate of $51.81M. In the same quarter a year ago, actual revenue was $67.77M, down -23.60% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $47.99M in the next fiscal year. The high estimate is $72.88M and the low estimate is $24M. The average revenue growth estimate for next year is down -7.40% from the average revenue estimate for this year.
